AstraZeneca Pharma gets CDSCO approval for Enhertu additional breast cancer indication

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹8110.00

prior close

₹8109.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+0.9% vs market

Pharmaceuticals peers, median of 165sector-0.8%+0.5% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.4

15m

-0.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-1.3+0.9-0.8+0.5

Next day

+1.1-0.8+1.9+0.2+0.9

+0.0-1.4+1.4-0.7+0.7

-0.1-0.3+0.2-0.3+0.2

+2.3+1.0+1.3+0.3+2.1

+1.2+1.5-0.2+0.7+0.5

-0.5+3.1-3.7+0.3-0.8

15d

-6.0+4.1-10.1+1.1-7.1

-12.6+4.8-17.3+1.6-14.1

-22.6+3.1-25.8+2.4-25.0

-23.1-3.6-19.5-2.0-21.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organization (CDSCO) to import and market Trastuzumab Deruxtecan (brand name Enhertu) for an additional indication. The drug is now approved for neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer, given before THP therapy (taxane, trastuzumab, and pertuzumab). This expands Enhertu's addressable market in India beyond its current approved uses, subject to any remaining statutory approvals before launch.

Likely market impact

Broadens Enhertu addressable market in India for early-stage HER2-positive breast cancer patients, supporting potential future revenue growth.